Head-To-Head Contrast: BioStem Technologies (OTCMKTS:BSEM) vs. Tarsus Pharmaceuticals (NASDAQ:TARS)

Tarsus Pharmaceuticals (NASDAQ:TARS) and BioStem Technologies (OTCMKTS:BSEM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.

Valuation and Earnings

This table compares Tarsus Pharmaceuticals and BioStem Technologies”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36 million	6.78	-$66.42 million	($1.62)	-44.38
BioStem Technologies	$47.48 million	1.82	-$7.09 million	($0.42)	-12.21

BioStem Technologies has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than BioStem Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings for Tarsus Pharmaceuticals and BioStem Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1	2	4	2	2.78
BioStem Technologies	0	1	0	0	2.00

Tarsus Pharmaceuticals presently has a consensus price target of $91.83, indicating a potential upside of 27.74%. Given Tarsus Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe Tarsus Pharmaceuticals is more favorable than BioStem Technologies.

Insider & Institutional Ownership

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 9.0% of Tarsus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Tarsus Pharmaceuticals and BioStem Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-14.72%	-19.63%	-12.70%
BioStem Technologies	N/A	N/A	N/A

Summary

Tarsus Pharmaceuticals beats BioStem Technologies on 8 of the 14 factors compared between the two stocks.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

About BioStem Technologies

BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.